logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

EHA 2020 – Fixed-duration ibrutinib in previously untreated CLL might spare immunotherapy for some

Is it possible for fit patients with chronic lymphocytic leukemia and a good prognosis to skip immunochemotherapy in favor of ibrutinib?